{"id":390084,"date":"2021-03-09T00:00:00","date_gmt":"2021-03-09T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0002-2021-biopharma-biosimilars-current-treatment-endocrinology-us-eu-2021\/"},"modified":"2026-04-21T11:23:56","modified_gmt":"2026-04-21T11:23:56","slug":"biosbi0002-2021-biopharma-biosimilars-current-treatment-endocrinology-us-eu-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0002-2021-biopharma-biosimilars-current-treatment-endocrinology-us-eu-2021\/","title":{"rendered":"Biosimilars | Current Treatment | Endocrinology | US\/EU | 2021"},"content":{"rendered":"<p>The biosimilar \/ follow-on insulin sector of the diabetes therapy market is evolving. Eli Lilly \/ Boehringer Ingelheim\u2019s Abasaglar \/ Basaglar was the first biosimilar \/ follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi\u2019s Admelog \/ Insulin lispro Sanofi. Subsequently, the EC approved Biocon \/ Viatris\u2019s (Mylan\u2019s) insulin glargine biosimilar Semglee, and the FDA approved this agent as an interchangeable biosimilar in July 2021.<\/p>\n<p>Endocrinologists\u2019 prescribing behavior\u00a0will directly impact the uptake of these products, including insulin brands such as Sanofi\u2019s Lantus and Eli Lilly\u2019s Humalog. Understanding physicians\u2019 attitude and behavior regarding biosimilars \/ follow-on insulins is critical for development and marketing strategies aimed at persuading endocrinologists to prescribe and drive biosimilar \/ follow-on insulin uptake.<\/p>\n<p>Clarivate\u2019s primary research with endocrinologists in the United States, France, and Germany allows clients to assess the dynamics determining current and future biosimilar \/ follow-on insulin uptake within the diabetes space.<\/p>\n<p>This report\u00a0includes the following topics:<\/p>\n<ul>\n<li>Physicians\u2019 current experience prescribing biosimilars \/ follow-on insulins.<\/li>\n<li>The main drivers and barriers influencing biosimilar \/ follow-on insulin uptake.<\/li>\n<li>The impact of cost and clinical data on biosimilar \/ follow-on insulin uptake.<\/li>\n<\/ul>\n<p><strong>Scope <\/strong><\/p>\n<p><strong>Markets covered:<\/strong> United States, France, and Germany.<\/p>\n<p><strong>Primary research: <\/strong>Online quantitative survey of 93\u00a0endocrinologists.<\/p>\n<p><em>Current Treatment: Physician Insights\u00a0<\/em>provides physician insights on treatment dynamics, prescribing behavior, and drivers of biosimilar use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n","protected":false},"template":"","class_list":["post-390084","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-biosimilars","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390084","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390084\/revisions"}],"predecessor-version":[{"id":393209,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390084\/revisions\/393209"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390084"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}